Yoki
Lv41
510 积分
2023-11-14 加入
-
Comprehensive analysis of human IL‐4 receptor subunits shows compartmentalization in steady state and dupilumab treatment
7天前
已完结
-
Efficacy and safety of rademikibart (CBP-201), a next-generation monoclonal antibody targeting IL-4Rα, in adults with moderate-to-severe atopic dermatitis: a phase 2 randomized trial (CBP-201-WW001)
11天前
已完结
-
The TL1A/DR3/DcR3 pathway in autoimmune rheumatic diseases
11天前
已完结
-
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
26天前
已完结
-
Abstract 10451: Efficacy and Safety of Ebronucimab, a Monoclonal Antibody Against Pcsk9, in Patients With Hyperlipidemia: Result From a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
1个月前
已关闭
-
Tafolecimab: First Approval
1个月前
已完结
-
TTK inhibition activates STING signal and promotes anti-PD1 immunotherapy in breast cancer
2个月前
已完结
-
Molecular basis of PD-1 blockade by dostarlimab, the FDA-approved antibody for cancer immunotherapy
2个月前
已完结
-
Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials
3个月前
已完结
-
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study
4个月前
已完结